Elena Bonazzoli
Yale University
CancerInternal medicinePathologyMolecular biologyChemistryIn vitroImmunohistochemistryIn vivoUterine serous carcinomaHER2/neuEndometrial cancerAntibody-drug conjugateOvarian cancerAntibody-dependent cell-mediated cytotoxicityCancer researchFlow cytometryCell growthMedicineCell cultureBiology
55Publications
16H-index
687Citations
Publications 53
Newest
#9Samir Zaidi (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 1
Source
#1Stefania Bellone (Yale University)H-Index: 29
#2Dana M. Roque (UMB: University of Maryland, Baltimore)H-Index: 18
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 33 authors...
Source
#1Jungmin Choi (Yale University)H-Index: 18
#2Aranzazu Manzano (Yale University)H-Index: 7
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 44 authors...
Uterine leiomyosarcomas (uLMS) are aggressive tumors arising from the smooth muscle layer of the uterus. We analyzed 83 uLMS sample genetics, including 56 from Yale and 27 from The Cancer Genome Atlas (TCGA). Among them, a total of 55 Yale samples including two patient-derived xenografts (PDXs) and 27 TCGA samples have whole-exome sequencing (WES) data; 10 Yale and 27 TCGA samples have RNA-sequencing (RNA-Seq) data; and 11 Yale and 10 TCGA samples have whole-genome sequencing (WGS) data. We foun...
Source
#1Joan Tymon-Rosario (Yale University)H-Index: 6
#2Paola Manara (Yale University)H-Index: 8
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 18 authors...
Source
#1Elena Bonazzoli (Yale University)H-Index: 16
#2Stefania Bellone (Yale University)H-Index: 29
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 11 authors...
Purpose: The prognosis for women with advanced or recurrent cervical cancer (CC) no longer responsive to radiation and/or chemotherapy remains poor. Whole-exome-sequencing (WES) studies have recently reported c-MYC gene amplification and HUWE1 gene mutations in a significant number of CC suggesting the HUWE1/c-MYC pathway as potential therapeutic target. We investigated HUWE1 and c-MYC expression in fresh-frozen CC and the potential activity of the novel BET bromodomain inhibitor GS-626510 (Gile...
Source
#1Elena Bonazzoli (Yale University)H-Index: 16
#2Stefania Bellone (Yale University)H-Index: 29
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 20 authors...
Abstract Objective Whole-exome-sequencing (WES) studies reported c-MYC gene-amplification and HUWE1 gene deletion/mutations in a significant number of cervical-cancer-patients (CC) suggesting HUWE1/c-MYC pathway as potential therapeutic target. We investigated HUWE1/c-MYC expression in fresh-frozen-CC and the activity of the novel BET inhibitor GS-626510 (Gilead-Science-Inc) against primary WES CC-cultures and CC-xenografts. Methods HUWE1 and c-MYC expression were evaluated by qRT-PCR in 23 CC i...
Source
#1Emanuele Perrone (Yale University)H-Index: 12
#2Paola Manara (Yale University)H-Index: 8
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 22 authors...
Endometrial cancer is the most common gynecologic malignancy in developed countries. The antibody-drug conjugate (ADC) sacituzumab govitecan (SG) targets trophoblast cell-surface antigen-2 (Trop-2) - a cell-surface glycoprotein highly expressed in many epithelial tumors - and delivers the active metabolite of irinotecan SN-38 to Trop-2-positive tumor cells. We evaluated Trop-2 expression in endometrial endometrioid carcinoma (EC) tissues and the activity of SG against primary poorly differentiat...
6 CitationsSource
#1Emanuele Perrone (Yale University)H-Index: 12
#1Emanuele Perrone (Yale University)H-Index: 1
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 22 authors...
Background Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy. Sacituzumab govitecan (SG) is a novel antibody-drug-conjugate (ADC) targeting trophoblast-antigen-2 (Trop-2), a cell surface glycoprotein highly expressed in many epithelial tumors, to deliver SN-38, the active metabolite of irinotecan. This study aimed to evaluate Trop-2 expression in EOC tissues and the preclinical activity of SG against primary EOC cell lines and xenografts. Methods Trop-2 expression was ass...
5 CitationsSource
#1Salvatore Lopez (Yale University)H-Index: 19
#2Emanuele Perrone (Yale University)H-Index: 12
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 24 authors...
// Salvatore Lopez 1 , 2 , 3 , Emanuele Perrone 1 , Stefania Bellone 1 , Elena Bonazzoli 1 , Burak Zeybek 1 , Chanhee Han 1 , Joan Tymon-Rosario 1 , Gary Altwerger 1 , Gulden Menderes 1 , Anna Bianchi 1 , Luca Zammataro 1 , Aranzazu Manzano 1 , Paola Manara 1 , Elena Ratner 1 , Dan-Arin Silasi 1 , Gloria S. Huang 1 , Masoud Azodi 1 , Peter E. Schwartz 1 , Francesco Raspagliesi 3 , Roberto Angioli 4 , Natalia Buza 5 , Pei Hui 5 , Heather M. Bond 6 and Alessandro D. Santin 1 1 Department of Obstet...
5 CitationsSource
#1Chanhee Han (Yale University)H-Index: 8
#2Emanuele Perrone (Yale University)H-Index: 12
Last. Alessandro D. Santin (Yale University)H-Index: 62
view all 24 authors...
Abstract Objective Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer with poor prognosis. Sacituzumab govitecan (SG) is a novel antibody-drug-conjugate (ADC) targeting trophoblast cell-surface antigen 2 (Trop-2), a transmembrane-calcium-signal-transducer, to deliver SN-38, the active metabolite of irinotecan. The objective of this study was to evaluate the expression of Trop-2 in USC and the preclinical activity of SG against primary USC cell-lines and xenografts. Met...
6 CitationsSource